Finding the Best Dose of Aspirin to Prevent Lynch Syndrome Cancers

Summary

A randomised double blind dose non-inferiority trial of a daily dose of 600mg versus 300mg versus 100mg of enteric coated aspirin as a cancer preventive in carriers of a germline pathological mismatch repair gene defect, Lynch Syndrome. Project 3 in the Cancer Prevention Programme (CaPP3).

Timeline

Start

2016-09

Primary completion

2027-09

Completion

2027-09

Publications

• Burn J, Borthwick GM, Elliott F, Macrae F, Ong KR, Kraus AC, Arber N, Mecklin JP, Alonso A, Woodward ER, Evans DG, Murray A, Snape K, Cleaver RE, Shaw A, Thomas HJW, Kumar AV, Halliday D, Side LE, Harrison RE, Davidson R, Armstrong R, Cook J, Hart R, Morrison PJ, Barwell JG, Donaldson A, Kemp Z, Murray J, Miedzybrodzka Z, Pottinger C, Berg J, Gallon R, Bishop DT; CaPP3 co-investigators. Aspirin for cancer prevention in individuals with Lynch syndrome: first results from the CaPP3 multicentre, randomised, double-blind, non-inferiority trial. Lancet Gastroenterol Hepatol. 2026 Jul 9:S2468-1253(26)00114-7. doi: 10.1016/S2468-1253(26)00114-7. Online ahead of print.

Drugs

Indications